Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 44 | 2024 | 17533 | 1.770 |
Why?
|
South Africa | 16 | 2024 | 1867 | 1.180 |
Why?
|
CD4 Lymphocyte Count | 12 | 2024 | 2587 | 0.990 |
Why?
|
Alendronate | 4 | 2005 | 174 | 0.690 |
Why?
|
Viral Load | 7 | 2024 | 3386 | 0.620 |
Why?
|
Beauty Culture | 1 | 2018 | 41 | 0.610 |
Why?
|
Anti-HIV Agents | 14 | 2024 | 4559 | 0.600 |
Why?
|
Speech Disorders | 1 | 2018 | 178 | 0.560 |
Why?
|
Contraception | 1 | 2018 | 361 | 0.480 |
Why?
|
Hair | 1 | 2018 | 508 | 0.470 |
Why?
|
Ambulatory Care Facilities | 4 | 2024 | 939 | 0.460 |
Why?
|
Constipation | 1 | 2018 | 568 | 0.430 |
Why?
|
Medication Adherence | 4 | 2024 | 2190 | 0.430 |
Why?
|
Estrogens, Conjugated (USP) | 2 | 2005 | 274 | 0.410 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2019 | 838 | 0.390 |
Why?
|
Patient Transfer | 1 | 2019 | 790 | 0.390 |
Why?
|
Autistic Disorder | 4 | 2021 | 1239 | 0.360 |
Why?
|
Lamivudine | 6 | 2017 | 368 | 0.350 |
Why?
|
Hormone Replacement Therapy | 2 | 2005 | 753 | 0.330 |
Why?
|
Anxiety | 4 | 2024 | 4668 | 0.330 |
Why?
|
Feasibility Studies | 5 | 2024 | 5302 | 0.330 |
Why?
|
Osteoporosis, Postmenopausal | 4 | 2007 | 399 | 0.320 |
Why?
|
Anti-Retroviral Agents | 6 | 2022 | 1787 | 0.310 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2022 | 4058 | 0.310 |
Why?
|
Decision Support Techniques | 1 | 2017 | 2003 | 0.280 |
Why?
|
Estrogen Replacement Therapy | 2 | 2005 | 1206 | 0.280 |
Why?
|
Models, Theoretical | 2 | 2017 | 3564 | 0.260 |
Why?
|
Tuberculosis | 1 | 2019 | 2012 | 0.260 |
Why?
|
Medroxyprogesterone | 1 | 2005 | 33 | 0.250 |
Why?
|
Adult | 54 | 2024 | 223038 | 0.250 |
Why?
|
Female | 73 | 2025 | 396101 | 0.250 |
Why?
|
Hip | 2 | 2017 | 249 | 0.250 |
Why?
|
Cost-Benefit Analysis | 9 | 2018 | 5526 | 0.250 |
Why?
|
Refugees | 3 | 2020 | 614 | 0.240 |
Why?
|
Reverse Transcriptase Inhibitors | 4 | 2017 | 618 | 0.230 |
Why?
|
Bone Density | 6 | 2017 | 3491 | 0.230 |
Why?
|
Antiretroviral Therapy, Highly Active | 6 | 2024 | 1899 | 0.230 |
Why?
|
Humans | 94 | 2025 | 765956 | 0.220 |
Why?
|
Benzoxazines | 4 | 2017 | 320 | 0.220 |
Why?
|
Progesterone Congeners | 1 | 2003 | 42 | 0.220 |
Why?
|
Pancreatitis | 2 | 2013 | 1087 | 0.210 |
Why?
|
Male | 63 | 2025 | 363691 | 0.200 |
Why?
|
Penicillins | 2 | 2016 | 404 | 0.200 |
Why?
|
Medroxyprogesterone Acetate | 1 | 2003 | 153 | 0.200 |
Why?
|
Brain Concussion | 2 | 2024 | 1432 | 0.200 |
Why?
|
Trichomonas Infections | 1 | 2022 | 41 | 0.190 |
Why?
|
Drug Monitoring | 2 | 2018 | 962 | 0.190 |
Why?
|
HIV-1 | 8 | 2020 | 6944 | 0.190 |
Why?
|
Stavudine | 5 | 2008 | 85 | 0.180 |
Why?
|
Bone Remodeling | 1 | 2005 | 577 | 0.180 |
Why?
|
Alkynes | 4 | 2017 | 326 | 0.180 |
Why?
|
Radiographic Image Enhancement | 3 | 2015 | 872 | 0.180 |
Why?
|
Forecasting | 2 | 2020 | 2936 | 0.180 |
Why?
|
Placebos | 3 | 2019 | 1659 | 0.180 |
Why?
|
Cyclopropanes | 4 | 2017 | 437 | 0.180 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 2006 | 2203 | 0.170 |
Why?
|
Didanosine | 4 | 2007 | 151 | 0.160 |
Why?
|
Positive-Pressure Respiration | 2 | 2023 | 711 | 0.160 |
Why?
|
Life Expectancy | 2 | 2016 | 1247 | 0.160 |
Why?
|
Models, Economic | 3 | 2018 | 716 | 0.160 |
Why?
|
Pregnancy, Unwanted | 1 | 2018 | 24 | 0.160 |
Why?
|
Bacteremia | 2 | 2016 | 989 | 0.150 |
Why?
|
Motor Activity | 2 | 2005 | 2704 | 0.150 |
Why?
|
Chlamydia Infections | 1 | 2022 | 364 | 0.150 |
Why?
|
Nelfinavir | 3 | 2007 | 68 | 0.150 |
Why?
|
Clinical Trials as Topic | 3 | 2018 | 8041 | 0.150 |
Why?
|
Pica | 1 | 2018 | 37 | 0.150 |
Why?
|
Community Health Services | 2 | 2020 | 657 | 0.150 |
Why?
|
Family Characteristics | 1 | 2023 | 1001 | 0.150 |
Why?
|
Child Health Services | 2 | 2020 | 645 | 0.140 |
Why?
|
Gonorrhea | 1 | 2022 | 354 | 0.140 |
Why?
|
Dental Care | 1 | 2020 | 286 | 0.140 |
Why?
|
Data Interpretation, Statistical | 1 | 2007 | 2686 | 0.140 |
Why?
|
Psychomotor Performance | 1 | 2005 | 1881 | 0.140 |
Why?
|
Cohort Studies | 10 | 2024 | 41647 | 0.140 |
Why?
|
Diazoxide | 3 | 2007 | 52 | 0.140 |
Why?
|
Middle Aged | 36 | 2025 | 223004 | 0.140 |
Why?
|
Drug Hypersensitivity | 2 | 2016 | 902 | 0.140 |
Why?
|
Muscle Hypotonia | 1 | 2018 | 167 | 0.140 |
Why?
|
Dideoxynucleosides | 1 | 2017 | 135 | 0.130 |
Why?
|
Staphylococcal Infections | 2 | 2016 | 1393 | 0.130 |
Why?
|
Algorithms | 4 | 2019 | 14071 | 0.130 |
Why?
|
Proportional Hazards Models | 3 | 2020 | 12509 | 0.130 |
Why?
|
Attention Deficit and Disruptive Behavior Disorders | 1 | 2018 | 307 | 0.130 |
Why?
|
Intraoperative Care | 1 | 2020 | 760 | 0.130 |
Why?
|
Cardioplegic Solutions | 2 | 2007 | 123 | 0.130 |
Why?
|
Pain Measurement | 2 | 2024 | 3561 | 0.130 |
Why?
|
Sputum | 1 | 2019 | 513 | 0.130 |
Why?
|
Respiratory Mechanics | 1 | 2020 | 717 | 0.130 |
Why?
|
Treatment Failure | 2 | 2017 | 2652 | 0.130 |
Why?
|
Sexually Transmitted Diseases | 1 | 2022 | 667 | 0.130 |
Why?
|
Absorptiometry, Photon | 4 | 2017 | 1707 | 0.130 |
Why?
|
Eczema | 1 | 2018 | 246 | 0.130 |
Why?
|
Vitamin D Deficiency | 1 | 2005 | 1348 | 0.130 |
Why?
|
Pilot Projects | 8 | 2025 | 8733 | 0.120 |
Why?
|
HIV | 4 | 2018 | 1585 | 0.120 |
Why?
|
Cross-Sectional Studies | 7 | 2022 | 26313 | 0.120 |
Why?
|
Probiotics | 1 | 2019 | 387 | 0.120 |
Why?
|
Educational Status | 1 | 2023 | 2513 | 0.120 |
Why?
|
Mass Screening | 4 | 2021 | 5445 | 0.120 |
Why?
|
Public Sector | 1 | 2017 | 264 | 0.120 |
Why?
|
Smoking Cessation | 2 | 2017 | 2084 | 0.120 |
Why?
|
Indinavir | 2 | 2005 | 73 | 0.120 |
Why?
|
Financing, Personal | 1 | 2017 | 310 | 0.120 |
Why?
|
Employee Performance Appraisal | 1 | 2015 | 86 | 0.120 |
Why?
|
Random Allocation | 1 | 2019 | 2395 | 0.120 |
Why?
|
Drug Substitution | 1 | 2017 | 292 | 0.120 |
Why?
|
Vitamin D | 2 | 2005 | 3272 | 0.120 |
Why?
|
Influenza Vaccines | 1 | 2022 | 778 | 0.120 |
Why?
|
Young Adult | 12 | 2024 | 59886 | 0.120 |
Why?
|
Caregivers | 2 | 2025 | 2307 | 0.110 |
Why?
|
Income | 1 | 2023 | 1874 | 0.110 |
Why?
|
Abdomen | 1 | 2020 | 1134 | 0.110 |
Why?
|
Needs Assessment | 1 | 2020 | 1138 | 0.110 |
Why?
|
Prevalence | 6 | 2022 | 15839 | 0.110 |
Why?
|
HIV Integrase Inhibitors | 1 | 2015 | 164 | 0.110 |
Why?
|
Social Support | 2 | 2020 | 2192 | 0.110 |
Why?
|
AIDS Serodiagnosis | 1 | 2014 | 220 | 0.110 |
Why?
|
Zidovudine | 4 | 2008 | 626 | 0.110 |
Why?
|
Myocardial Reperfusion Injury | 3 | 2007 | 478 | 0.100 |
Why?
|
Adolescent | 13 | 2024 | 88832 | 0.100 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2015 | 295 | 0.100 |
Why?
|
Heart Arrest | 1 | 2023 | 1516 | 0.100 |
Why?
|
Lung Diseases | 1 | 2023 | 1940 | 0.100 |
Why?
|
Models, Statistical | 4 | 2019 | 5089 | 0.100 |
Why?
|
Tomography, Spiral Computed | 1 | 2014 | 273 | 0.100 |
Why?
|
Drug Combinations | 2 | 2017 | 2077 | 0.100 |
Why?
|
Double-Blind Method | 6 | 2007 | 12437 | 0.100 |
Why?
|
Internationality | 1 | 2018 | 1007 | 0.100 |
Why?
|
Indomethacin | 1 | 2013 | 322 | 0.100 |
Why?
|
Dietary Supplements | 1 | 2005 | 3426 | 0.100 |
Why?
|
Health Services Needs and Demand | 1 | 2020 | 1406 | 0.100 |
Why?
|
Models, Educational | 1 | 2015 | 376 | 0.100 |
Why?
|
Anesthesia | 1 | 2023 | 1590 | 0.100 |
Why?
|
Research Design | 1 | 2007 | 6208 | 0.090 |
Why?
|
United States | 14 | 2021 | 72898 | 0.090 |
Why?
|
Aged | 27 | 2025 | 171114 | 0.090 |
Why?
|
Aging | 4 | 2020 | 8731 | 0.090 |
Why?
|
Prospective Studies | 14 | 2023 | 54806 | 0.090 |
Why?
|
Mind-Body Therapies | 2 | 2024 | 294 | 0.090 |
Why?
|
Influenza, Human | 1 | 2022 | 1539 | 0.090 |
Why?
|
Health Care Costs | 3 | 2018 | 3242 | 0.090 |
Why?
|
Computer Simulation | 3 | 2019 | 6255 | 0.090 |
Why?
|
Drugs, Generic | 1 | 2015 | 456 | 0.090 |
Why?
|
Research Support as Topic | 1 | 2015 | 696 | 0.090 |
Why?
|
Radiography, Dual-Energy Scanned Projection | 1 | 2013 | 208 | 0.090 |
Why?
|
Self Report | 2 | 2024 | 3771 | 0.090 |
Why?
|
Smoking | 2 | 2017 | 9081 | 0.090 |
Why?
|
Dementia | 1 | 2025 | 2744 | 0.080 |
Why?
|
Depression | 2 | 2021 | 8230 | 0.080 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 2 | 2014 | 1224 | 0.080 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 1 | 2013 | 520 | 0.080 |
Why?
|
Homosexuality, Male | 1 | 2018 | 1342 | 0.080 |
Why?
|
Continuity of Patient Care | 1 | 2017 | 1078 | 0.080 |
Why?
|
Treatment Outcome | 12 | 2024 | 65189 | 0.080 |
Why?
|
Developmental Disabilities | 1 | 2018 | 1519 | 0.080 |
Why?
|
Drug Therapy, Combination | 5 | 2007 | 6309 | 0.080 |
Why?
|
Primary Health Care | 3 | 2021 | 4736 | 0.080 |
Why?
|
HIV Protease Inhibitors | 3 | 2008 | 430 | 0.080 |
Why?
|
Oxazines | 2 | 2015 | 358 | 0.080 |
Why?
|
Contrast Media | 4 | 2015 | 5329 | 0.080 |
Why?
|
Body Composition | 3 | 2007 | 2439 | 0.080 |
Why?
|
Family | 1 | 2020 | 3209 | 0.080 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2014 | 730 | 0.080 |
Why?
|
RNA, Viral | 1 | 2017 | 2864 | 0.080 |
Why?
|
Infant | 3 | 2020 | 36385 | 0.080 |
Why?
|
Point-of-Care Systems | 1 | 2017 | 1217 | 0.080 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2015 | 705 | 0.080 |
Why?
|
Uganda | 3 | 2020 | 1353 | 0.080 |
Why?
|
Anti-Bacterial Agents | 3 | 2016 | 7478 | 0.080 |
Why?
|
Cooperative Behavior | 1 | 2015 | 1509 | 0.070 |
Why?
|
Staphylococcus aureus | 1 | 2016 | 1424 | 0.070 |
Why?
|
Academic Medical Centers | 2 | 2015 | 2780 | 0.070 |
Why?
|
Mortality | 1 | 2019 | 2904 | 0.070 |
Why?
|
Osteocalcin | 2 | 2007 | 271 | 0.070 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2020 | 4405 | 0.070 |
Why?
|
Geranyltranstransferase | 1 | 2007 | 5 | 0.070 |
Why?
|
Time Factors | 11 | 2020 | 40065 | 0.070 |
Why?
|
Faculty, Medical | 1 | 2015 | 1219 | 0.070 |
Why?
|
Research | 1 | 2015 | 1975 | 0.070 |
Why?
|
Radiation Injuries | 1 | 2014 | 1181 | 0.070 |
Why?
|
Trust | 2 | 2022 | 533 | 0.070 |
Why?
|
Child | 9 | 2021 | 80563 | 0.070 |
Why?
|
Vascular Diseases | 1 | 2015 | 1159 | 0.070 |
Why?
|
Program Evaluation | 1 | 2015 | 2499 | 0.060 |
Why?
|
Isotonic Solutions | 1 | 2006 | 121 | 0.060 |
Why?
|
Testosterone | 2 | 2007 | 2494 | 0.060 |
Why?
|
Health Services Accessibility | 2 | 2020 | 5506 | 0.060 |
Why?
|
Delivery of Health Care | 2 | 2020 | 5369 | 0.060 |
Why?
|
Pregnancy | 4 | 2022 | 30258 | 0.060 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7836 | 0.060 |
Why?
|
Alkaline Phosphatase | 2 | 2007 | 854 | 0.060 |
Why?
|
Body Fat Distribution | 1 | 2006 | 246 | 0.060 |
Why?
|
Densitometry | 1 | 2005 | 150 | 0.060 |
Why?
|
Nucleosides | 1 | 2005 | 130 | 0.060 |
Why?
|
Collagen Type I | 2 | 2007 | 615 | 0.060 |
Why?
|
Anti-Infective Agents, Local | 1 | 2007 | 245 | 0.060 |
Why?
|
Pediatrics | 1 | 2020 | 3606 | 0.060 |
Why?
|
Abdominal Fat | 1 | 2006 | 217 | 0.060 |
Why?
|
Canada | 2 | 2020 | 2119 | 0.060 |
Why?
|
Bone and Bones | 2 | 2005 | 2554 | 0.060 |
Why?
|
Hydroxyurea | 1 | 2005 | 284 | 0.060 |
Why?
|
Lactates | 1 | 2005 | 398 | 0.060 |
Why?
|
Hyperinsulinism | 1 | 2007 | 402 | 0.050 |
Why?
|
Kidney Neoplasms | 2 | 2014 | 4274 | 0.050 |
Why?
|
Minerals | 1 | 2005 | 278 | 0.050 |
Why?
|
Thiazolidinediones | 1 | 2007 | 459 | 0.050 |
Why?
|
Interleukin-2 | 3 | 2005 | 1896 | 0.050 |
Why?
|
Comorbidity | 1 | 2018 | 10563 | 0.050 |
Why?
|
Kidney | 3 | 2014 | 7066 | 0.050 |
Why?
|
HN Protein | 1 | 2003 | 8 | 0.050 |
Why?
|
Drug Administration Schedule | 4 | 2020 | 4850 | 0.050 |
Why?
|
Femur Neck | 1 | 2005 | 316 | 0.050 |
Why?
|
Blood Specimen Collection | 1 | 2005 | 238 | 0.050 |
Why?
|
Cardiotonic Agents | 1 | 2006 | 538 | 0.050 |
Why?
|
Lung Neoplasms | 2 | 2018 | 13451 | 0.050 |
Why?
|
Calcium | 2 | 2007 | 5767 | 0.050 |
Why?
|
Macaca fascicularis | 1 | 2005 | 907 | 0.050 |
Why?
|
Cholinergic Fibers | 1 | 2003 | 68 | 0.050 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2018 | 3718 | 0.050 |
Why?
|
Melanoma | 3 | 2010 | 5719 | 0.050 |
Why?
|
Epilepsy | 1 | 2018 | 3320 | 0.050 |
Why?
|
Schools | 2 | 2023 | 1492 | 0.050 |
Why?
|
Carotid Artery Thrombosis | 1 | 2002 | 47 | 0.050 |
Why?
|
Telemedicine | 1 | 2020 | 3105 | 0.050 |
Why?
|
Paclitaxel | 1 | 2010 | 1728 | 0.050 |
Why?
|
Pulmonary Eosinophilia | 1 | 2003 | 78 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2024 | 10383 | 0.050 |
Why?
|
Quality of Life | 2 | 2025 | 13461 | 0.050 |
Why?
|
Respiratory Syncytial Viruses | 1 | 2003 | 168 | 0.050 |
Why?
|
Child, Preschool | 3 | 2020 | 42500 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 3 | 2014 | 20660 | 0.050 |
Why?
|
Aged, 80 and over | 9 | 2018 | 59488 | 0.050 |
Why?
|
Postoperative Complications | 2 | 2023 | 15747 | 0.050 |
Why?
|
Post-Concussion Syndrome | 1 | 2024 | 257 | 0.050 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2005 | 791 | 0.050 |
Why?
|
Albuminuria | 1 | 2005 | 660 | 0.050 |
Why?
|
Multicenter Studies as Topic | 2 | 2023 | 1731 | 0.050 |
Why?
|
Mitochondria, Heart | 1 | 2002 | 227 | 0.050 |
Why?
|
Risk Factors | 11 | 2019 | 74836 | 0.050 |
Why?
|
Postural Balance | 1 | 2005 | 637 | 0.040 |
Why?
|
Stents | 1 | 2013 | 3213 | 0.040 |
Why?
|
Prosencephalon | 1 | 2003 | 305 | 0.040 |
Why?
|
Colonic Diseases, Functional | 1 | 2000 | 38 | 0.040 |
Why?
|
Area Under Curve | 1 | 2005 | 1638 | 0.040 |
Why?
|
Body Weight | 3 | 2006 | 4622 | 0.040 |
Why?
|
Interleukin-13 | 1 | 2003 | 388 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2010 | 11868 | 0.040 |
Why?
|
Oxygen Consumption | 1 | 2007 | 1870 | 0.040 |
Why?
|
Diphosphonates | 1 | 2005 | 625 | 0.040 |
Why?
|
Dehydroepiandrosterone | 1 | 2021 | 248 | 0.040 |
Why?
|
Sulfonamides | 1 | 2010 | 1984 | 0.040 |
Why?
|
Specimen Handling | 1 | 2005 | 704 | 0.040 |
Why?
|
Simian immunodeficiency virus | 1 | 2005 | 812 | 0.040 |
Why?
|
Stroke | 2 | 2018 | 9747 | 0.040 |
Why?
|
Dacarbazine | 1 | 2002 | 552 | 0.040 |
Why?
|
Biomarkers, Pharmacological | 1 | 2020 | 162 | 0.040 |
Why?
|
Pyrazoles | 1 | 2010 | 2033 | 0.040 |
Why?
|
Carcinoma, Renal Cell | 2 | 2005 | 3181 | 0.040 |
Why?
|
Biomedical Research | 1 | 2015 | 3458 | 0.040 |
Why?
|
Africa South of the Sahara | 1 | 2022 | 751 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2019 | 12240 | 0.040 |
Why?
|
Metformin | 1 | 2007 | 904 | 0.040 |
Why?
|
Head and Neck Neoplasms | 1 | 2013 | 2921 | 0.040 |
Why?
|
Infarction, Middle Cerebral Artery | 1 | 2002 | 485 | 0.040 |
Why?
|
Hypertension | 1 | 2019 | 8626 | 0.040 |
Why?
|
Femur | 1 | 2005 | 1310 | 0.040 |
Why?
|
Macaca mulatta | 1 | 2005 | 2341 | 0.040 |
Why?
|
Observer Variation | 2 | 2015 | 2615 | 0.040 |
Why?
|
Estrogens | 1 | 2005 | 1529 | 0.040 |
Why?
|
Walking | 1 | 2005 | 1198 | 0.040 |
Why?
|
Bone Density Conservation Agents | 1 | 2005 | 791 | 0.040 |
Why?
|
Respiratory Syncytial Virus Infections | 1 | 2003 | 365 | 0.040 |
Why?
|
Case Management | 1 | 2020 | 277 | 0.040 |
Why?
|
Mozambique | 1 | 2017 | 55 | 0.040 |
Why?
|
Pituitary-Adrenal System | 1 | 2021 | 547 | 0.040 |
Why?
|
Statistics, Nonparametric | 2 | 2017 | 2845 | 0.040 |
Why?
|
Accidental Falls | 1 | 2005 | 1078 | 0.040 |
Why?
|
Skin Neoplasms | 2 | 2010 | 5849 | 0.040 |
Why?
|
Universities | 1 | 2023 | 998 | 0.040 |
Why?
|
Reproducibility of Results | 4 | 2019 | 20125 | 0.040 |
Why?
|
Adipose Tissue | 2 | 2006 | 3312 | 0.030 |
Why?
|
Rural Population | 2 | 2018 | 2317 | 0.030 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2021 | 697 | 0.030 |
Why?
|
Fentanyl | 1 | 2000 | 457 | 0.030 |
Why?
|
Resilience, Psychological | 1 | 2025 | 806 | 0.030 |
Why?
|
North America | 1 | 2020 | 1285 | 0.030 |
Why?
|
Collagen | 1 | 2005 | 2618 | 0.030 |
Why?
|
Tissue Plasminogen Activator | 1 | 2002 | 1167 | 0.030 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2020 | 390 | 0.030 |
Why?
|
Methicillin | 1 | 2016 | 61 | 0.030 |
Why?
|
Activities of Daily Living | 1 | 2005 | 2415 | 0.030 |
Why?
|
Endothelium, Vascular | 1 | 2008 | 4427 | 0.030 |
Why?
|
Pain Threshold | 1 | 2000 | 604 | 0.030 |
Why?
|
Boston | 2 | 2007 | 9338 | 0.030 |
Why?
|
Regression Analysis | 3 | 2016 | 6321 | 0.030 |
Why?
|
Postmenopause | 1 | 2005 | 2515 | 0.030 |
Why?
|
Appointments and Schedules | 1 | 2020 | 444 | 0.030 |
Why?
|
Sex Characteristics | 1 | 2006 | 2643 | 0.030 |
Why?
|
Demography | 2 | 2015 | 1641 | 0.030 |
Why?
|
Myocardial Ischemia | 1 | 2006 | 2128 | 0.030 |
Why?
|
Kenya | 1 | 2018 | 758 | 0.030 |
Why?
|
HIV-Associated Lipodystrophy Syndrome | 2 | 2007 | 137 | 0.030 |
Why?
|
Brachiocephalic Veins | 1 | 2015 | 21 | 0.030 |
Why?
|
Forearm | 1 | 2017 | 427 | 0.030 |
Why?
|
Subclavian Vein | 1 | 2015 | 58 | 0.030 |
Why?
|
Attitude | 1 | 2020 | 770 | 0.030 |
Why?
|
Voluntary Programs | 1 | 2014 | 48 | 0.030 |
Why?
|
beta-Lactams | 1 | 2016 | 158 | 0.030 |
Why?
|
Iopamidol | 1 | 2015 | 188 | 0.030 |
Why?
|
Skin Tests | 1 | 2016 | 630 | 0.030 |
Why?
|
Blood Circulation | 1 | 2015 | 248 | 0.030 |
Why?
|
Michigan | 1 | 2015 | 328 | 0.030 |
Why?
|
Hypoglycemic Agents | 1 | 2007 | 3110 | 0.030 |
Why?
|
Registries | 2 | 2020 | 8297 | 0.030 |
Why?
|
Blood Glucose | 2 | 2005 | 6425 | 0.030 |
Why?
|
Phlebography | 1 | 2015 | 328 | 0.030 |
Why?
|
Jugular Veins | 1 | 2015 | 211 | 0.030 |
Why?
|
Health Resources | 1 | 2020 | 949 | 0.030 |
Why?
|
Obesity | 3 | 2021 | 13075 | 0.030 |
Why?
|
Mitochondria | 1 | 2007 | 3673 | 0.030 |
Why?
|
Tanzania | 1 | 2018 | 1407 | 0.030 |
Why?
|
Administration, Rectal | 1 | 2013 | 69 | 0.030 |
Why?
|
Vancomycin | 1 | 2016 | 504 | 0.030 |
Why?
|
Hydrocortisone | 1 | 2021 | 1827 | 0.030 |
Why?
|
Biostatistics | 1 | 2015 | 162 | 0.030 |
Why?
|
Budgets | 1 | 2015 | 232 | 0.030 |
Why?
|
Clinical Laboratory Techniques | 1 | 2018 | 747 | 0.030 |
Why?
|
Clinical Competence | 2 | 2020 | 4863 | 0.030 |
Why?
|
Sex Factors | 1 | 2007 | 10602 | 0.030 |
Why?
|
Peptides | 1 | 2005 | 4331 | 0.030 |
Why?
|
Writing | 1 | 2015 | 199 | 0.030 |
Why?
|
Incidence | 2 | 2015 | 21480 | 0.030 |
Why?
|
C-Reactive Protein | 1 | 2004 | 3850 | 0.030 |
Why?
|
Insulin Resistance | 2 | 2005 | 3985 | 0.030 |
Why?
|
Age Factors | 2 | 2007 | 18380 | 0.030 |
Why?
|
Retrospective Studies | 7 | 2016 | 81515 | 0.020 |
Why?
|
Authorship | 1 | 2015 | 288 | 0.020 |
Why?
|
Survivors | 1 | 2023 | 2372 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2020 | 2354 | 0.020 |
Why?
|
Pandemics | 2 | 2022 | 8701 | 0.020 |
Why?
|
Faculty | 1 | 2015 | 384 | 0.020 |
Why?
|
Kidney Function Tests | 1 | 2014 | 683 | 0.020 |
Why?
|
Radiation Tolerance | 1 | 2014 | 475 | 0.020 |
Why?
|
Delayed-Action Preparations | 1 | 2015 | 967 | 0.020 |
Why?
|
Brazil | 1 | 2016 | 1248 | 0.020 |
Why?
|
Anxiety Disorders | 1 | 2023 | 2736 | 0.020 |
Why?
|
Wounds and Injuries | 1 | 2024 | 2511 | 0.020 |
Why?
|
Subtraction Technique | 1 | 2014 | 512 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2016 | 1187 | 0.020 |
Why?
|
Lipids | 3 | 2007 | 3316 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2018 | 1737 | 0.020 |
Why?
|
Feedback | 1 | 2015 | 796 | 0.020 |
Why?
|
Spine | 1 | 2017 | 1128 | 0.020 |
Why?
|
Rabbits | 2 | 2007 | 4734 | 0.020 |
Why?
|
Pyridones | 1 | 2015 | 816 | 0.020 |
Why?
|
Eosinophils | 1 | 2015 | 945 | 0.020 |
Why?
|
Vaccination | 1 | 2022 | 3426 | 0.020 |
Why?
|
Microbial Sensitivity Tests | 1 | 2016 | 1971 | 0.020 |
Why?
|
Immunotherapy | 1 | 2005 | 4752 | 0.020 |
Why?
|
Risk | 2 | 2015 | 9591 | 0.020 |
Why?
|
Urban Population | 1 | 2017 | 2040 | 0.020 |
Why?
|
Pulmonary Veins | 1 | 2015 | 757 | 0.020 |
Why?
|
Heart Atria | 1 | 2015 | 1363 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2022 | 3229 | 0.020 |
Why?
|
Tumor Burden | 1 | 2014 | 1885 | 0.020 |
Why?
|
Cognition | 1 | 2005 | 7048 | 0.020 |
Why?
|
Teaching | 1 | 2015 | 1169 | 0.020 |
Why?
|
Heart Ventricles | 2 | 2015 | 3832 | 0.020 |
Why?
|
Recovery of Function | 1 | 2018 | 2966 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2005 | 10261 | 0.020 |
Why?
|
Lung | 2 | 2023 | 10033 | 0.020 |
Why?
|
Drug Costs | 1 | 2015 | 1193 | 0.020 |
Why?
|
Allergens | 1 | 2015 | 1436 | 0.020 |
Why?
|
Health Personnel | 1 | 2021 | 3390 | 0.020 |
Why?
|
Triage | 1 | 2014 | 996 | 0.020 |
Why?
|
Neoplasm Metastasis | 2 | 2010 | 4893 | 0.020 |
Why?
|
Brachial Artery | 1 | 2008 | 375 | 0.020 |
Why?
|
Apoptosis | 1 | 2002 | 9514 | 0.020 |
Why?
|
Ritonavir | 1 | 2008 | 330 | 0.020 |
Why?
|
Parents | 1 | 2020 | 3592 | 0.020 |
Why?
|
Communication | 1 | 2020 | 3916 | 0.020 |
Why?
|
Artifacts | 1 | 2015 | 1893 | 0.020 |
Why?
|
Pulmonary Artery | 1 | 2015 | 1935 | 0.020 |
Why?
|
Decision Support Systems, Clinical | 1 | 2015 | 1175 | 0.020 |
Why?
|
Pyrimidinones | 1 | 2008 | 384 | 0.020 |
Why?
|
Myocardial Reperfusion | 1 | 2007 | 338 | 0.020 |
Why?
|
Waist-Hip Ratio | 1 | 2007 | 520 | 0.020 |
Why?
|
Neoplasms | 1 | 2014 | 22340 | 0.020 |
Why?
|
Piperazines | 1 | 2015 | 2549 | 0.010 |
Why?
|
Exercise | 1 | 2021 | 5937 | 0.010 |
Why?
|
Coronary Artery Disease | 1 | 2004 | 6546 | 0.010 |
Why?
|
Sodium Fluoride | 1 | 2005 | 60 | 0.010 |
Why?
|
Oxalates | 1 | 2005 | 99 | 0.010 |
Why?
|
Analgesics, Opioid | 1 | 2000 | 3835 | 0.010 |
Why?
|
Ambulatory Care | 1 | 2015 | 2778 | 0.010 |
Why?
|
Blood Preservation | 1 | 2005 | 168 | 0.010 |
Why?
|
Survival Analysis | 1 | 2016 | 10070 | 0.010 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2005 | 218 | 0.010 |
Why?
|
Diet | 1 | 2021 | 8086 | 0.010 |
Why?
|
Hospitals | 1 | 2017 | 3888 | 0.010 |
Why?
|
Potassium Channels | 1 | 2006 | 534 | 0.010 |
Why?
|
Magnesium | 1 | 2007 | 813 | 0.010 |
Why?
|
Acidosis, Lactic | 1 | 2005 | 144 | 0.010 |
Why?
|
Blood Pressure | 1 | 2019 | 8532 | 0.010 |
Why?
|
Body Size | 1 | 2006 | 459 | 0.010 |
Why?
|
Receptors, Interleukin-4 | 1 | 2003 | 65 | 0.010 |
Why?
|
Respiratory Syncytial Virus Vaccines | 1 | 2003 | 37 | 0.010 |
Why?
|
Potassium | 1 | 2007 | 1311 | 0.010 |
Why?
|
Adenine | 1 | 2008 | 994 | 0.010 |
Why?
|
Vaccines, Inactivated | 1 | 2003 | 185 | 0.010 |
Why?
|
Viremia | 1 | 2005 | 727 | 0.010 |
Why?
|
Cytokines | 2 | 2010 | 7421 | 0.010 |
Why?
|
Injections, Subcutaneous | 1 | 2003 | 682 | 0.010 |
Why?
|
In Situ Nick-End Labeling | 1 | 2002 | 610 | 0.010 |
Why?
|
bcl-2-Associated X Protein | 1 | 2002 | 283 | 0.010 |
Why?
|
Cerebral Infarction | 1 | 2006 | 970 | 0.010 |
Why?
|
Perfusion | 1 | 2006 | 1407 | 0.010 |
Why?
|
Formaldehyde | 1 | 2003 | 352 | 0.010 |
Why?
|
Vaccinia virus | 1 | 2003 | 327 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 2002 | 9071 | 0.010 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2006 | 1333 | 0.010 |
Why?
|
Vinblastine | 1 | 2002 | 483 | 0.010 |
Why?
|
Neutralization Tests | 1 | 2003 | 735 | 0.010 |
Why?
|
Species Specificity | 1 | 2005 | 2406 | 0.010 |
Why?
|
Antibody Specificity | 1 | 2003 | 1061 | 0.010 |
Why?
|
Cytoplasm | 1 | 2005 | 1500 | 0.010 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2002 | 429 | 0.010 |
Why?
|
Interleukin-12 | 1 | 2003 | 579 | 0.010 |
Why?
|
Maximum Tolerated Dose | 1 | 2003 | 898 | 0.010 |
Why?
|
Adenosine Triphosphate | 1 | 2007 | 1999 | 0.010 |
Why?
|
Immunohistochemistry | 2 | 2005 | 11022 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2019 | 5891 | 0.010 |
Why?
|
Caspase 3 | 1 | 2002 | 731 | 0.010 |
Why?
|
Insulin | 2 | 2006 | 6599 | 0.010 |
Why?
|
Injections, Intravenous | 1 | 2002 | 1377 | 0.010 |
Why?
|
Glucose Tolerance Test | 1 | 2003 | 1180 | 0.010 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2002 | 633 | 0.010 |
Why?
|
Creatinine | 1 | 2005 | 1915 | 0.010 |
Why?
|
Caspases | 1 | 2002 | 880 | 0.010 |
Why?
|
Disease Susceptibility | 1 | 2006 | 1789 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 2002 | 2548 | 0.010 |
Why?
|
Viral Envelope Proteins | 1 | 2003 | 640 | 0.010 |
Why?
|
Receptors, Opioid, mu | 1 | 2000 | 165 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2020 | 39194 | 0.010 |
Why?
|
Interleukin-4 | 1 | 2003 | 1162 | 0.010 |
Why?
|
Models, Biological | 1 | 2015 | 9443 | 0.010 |
Why?
|
Immunization | 1 | 2003 | 1219 | 0.010 |
Why?
|
HIV Antibodies | 1 | 2005 | 1337 | 0.010 |
Why?
|
Interferon-alpha | 1 | 2002 | 910 | 0.010 |
Why?
|
Dyslipidemias | 1 | 2005 | 869 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2013 | 14652 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2013 | 12976 | 0.010 |
Why?
|
Family Health | 1 | 2003 | 1253 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2002 | 2229 | 0.010 |
Why?
|
Th2 Cells | 1 | 2003 | 1075 | 0.010 |
Why?
|
Cardiopulmonary Bypass | 1 | 2002 | 1090 | 0.010 |
Why?
|
Disease Progression | 1 | 2014 | 13631 | 0.010 |
Why?
|
Cisplatin | 1 | 2002 | 1658 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2016 | 26349 | 0.010 |
Why?
|
Animals | 5 | 2007 | 168759 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2002 | 1410 | 0.010 |
Why?
|
Rectum | 1 | 2000 | 896 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2003 | 6220 | 0.010 |
Why?
|
Ventricular Function, Left | 1 | 2006 | 3928 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2002 | 6493 | 0.010 |
Why?
|
Swine | 1 | 2002 | 5988 | 0.010 |
Why?
|
Genotype | 1 | 2007 | 13024 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2002 | 6832 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2000 | 6203 | 0.010 |
Why?
|
Antibodies, Viral | 1 | 2003 | 3211 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2007 | 14749 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2002 | 4520 | 0.010 |
Why?
|
Cell Line | 1 | 2003 | 15543 | 0.000 |
Why?
|
Cell Line, Tumor | 1 | 2005 | 17075 | 0.000 |
Why?
|
Survival Rate | 1 | 2002 | 12795 | 0.000 |
Why?
|
Mice, Knockout | 1 | 2003 | 14447 | 0.000 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2007 | 16047 | 0.000 |
Why?
|
Prognosis | 1 | 2005 | 29921 | 0.000 |
Why?
|
Severity of Illness Index | 1 | 2002 | 15880 | 0.000 |
Why?
|
Inflammation | 1 | 2003 | 10850 | 0.000 |
Why?
|
Case-Control Studies | 1 | 2000 | 22222 | 0.000 |
Why?
|
Alzheimer Disease | 1 | 2003 | 8728 | 0.000 |
Why?
|
Cardiovascular Diseases | 1 | 2005 | 15651 | 0.000 |
Why?
|
Mice | 1 | 2003 | 81818 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2002 | 36532 | 0.000 |
Why?
|